Stian Foss

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Fusion of IgG antibodies to albumin inhibits transport across the placenta.

Fusion of IgG antibodies to albumin inhibits transport across the placenta.

Journal: Science immunology
Published: August 14, 2026

Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases.

Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases.

Journal: Cell systems
Published: January 15, 2025

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.

Journal: PNAS nexus
Published: July 11, 2024

An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models.

An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models.

Journal: Nature communications
Published: January 23, 2024

Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties.

Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties.

Journal: International journal of retina and vitreous
Published: September 26, 2023

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.

Journal: Nature communications
Published: April 07, 2023

Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.

Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.

Journal: Science (New York, N.Y.)
Published: March 30, 2023

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.

Journal: Frontiers in immunology
Published: March 03, 2023

Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942.

Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942.

Journal: Cells
Published: May 17, 2022

Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life.

Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life.

Journal: Communications biology
Published: May 11, 2022

Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge.

Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge.

Journal: Science immunology
Published: April 29, 2022

Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?

Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?

Journal: Cells
Published: November 26, 2021
Showing 1-12 of 38

Last Updated: 09/26/2026